Compare TSQ & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | UNCY |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 100.6M |
| IPO Year | 2014 | 2021 |
| Metric | TSQ | UNCY |
|---|---|---|
| Price | $1.52 | $3.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $10.00 | ★ $28.40 |
| AVG Volume (30 Days) | 197.5K | ★ 1.0M |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | ★ 53.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,380,000.00 | $675,000.00 |
| Revenue This Year | $0.91 | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $3.33 |
| 52 Week High | $7.97 | $8.74 |
| Indicator | TSQ | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 11.47 | 46.57 |
| Support Level | N/A | $3.34 |
| Resistance Level | $7.35 | $4.18 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 0.80 | 60.38 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.